The Q2 2017 EPS Estimates for TG Therapeutics Inc Increased by Jefferies Group (TGTX)

The Q2 2017 EPS Estimates for TG Therapeutics Inc Increased by Jefferies Group (TGTX)

Several other analysts also recently weighed in on TGTX. Zacks Investment Research raised shares of TG Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, January 25th. Aegis initiated coverage on shares of TG Therapeutics in a research report on Wednesday, February 22nd. They set a “buy” rating and a $26.00 target price on the stock. FBR & Co reissued an “outperform” rating and set a $26.00 target price (up previously from $24.00) on shares of TG Therapeutics in a research report on Monday, March 6th. Langenberg & Company boosted their target price on shares of TG Therapeutics from $28.00 to $30.00 and gave the stock a “positive” rating in a research report on Tuesday, March 7th. Finally, HC Wainwright reissued a “buy” rating and set a $18.00 target price on shares of TG Therapeutics in a research report on Tuesday, March 7th. One equities research analyst has rated the stock with a hold rating and ten have given a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $23.17.

TG Therapeutics Inc (NASDAQ:TGTX) – Equities research analysts at Jefferies Group upped their Q2 2017 EPS estimates for TG Therapeutics in a research note issued on Monday. Jefferies Group analyst M. Andrews now anticipates that the biopharmaceutical company will earn ($0.41) per share for the quarter, up from their prior forecast of ($0.42). Jefferies Group has a “Buy” rating and a $23.00 price objective on the stock. Jefferies Group also issued estimates for TG Therapeutics’ Q3 2017 earnings at ($0.43) EPS, Q4 2017 earnings at ($0.44) EPS, FY2017 earnings at ($1.79) EPS, FY2018 earnings at ($1.84) EPS, FY2019 earnings at ($1.98) EPS, FY2020 earnings at ($1.24) EPS and FY2021 earnings at ($0.55) EPS.

TG Therapeutics (NASDAQ:TGTX) last issued its earnings results on Friday, May 5th. The biopharmaceutical company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by $0.10. The firm had revenue of $0.04 million during the quarter, compared to the consensus estimate of $0.04 million. TG Therapeutics had a negative return on equity of 83.18% and a negative net margin of 47,494.08%. Hedge funds have recently made changes to their positions in the stock. RA Capital Management LLC boosted its stake in shares of TG Therapeutics by 2.2% in the third quarter. RA Capital Management LLC now owns 4,631,114 shares of the biopharmaceutical company’s stock valued at $35,845,000 after buying an additional 99,400 shares during the last quarter. Baker BROS. Advisors LP acquired a new stake in shares of TG Therapeutics during the third quarter valued at approximately $15,511,000. Jennison Associates LLC acquired a new stake in shares of TG Therapeutics during the first quarter valued at approximately $16,034,000. Columbus Circle Investors boosted its stake in shares of TG Therapeutics by 29.3% in the first quarter. Columbus Circle Investors now owns 1,004,421 shares of the biopharmaceutical company’s stock valued at $11,702,000 after buying an additional 227,722 shares during the last quarter. Finally, State Street Corp boosted its stake in shares of TG Therapeutics by 6.7% in the fourth quarter. State Street Corp now owns 679,115 shares of the biopharmaceutical company’s stock valued at $3,157,000 after buying an additional 42,760 shares during the last quarter. Institutional investors and hedge funds own 50.08% of the company’s stock.

In other TG Therapeutics news, Director Laurence N. Charney sold 7,000 shares of TG Therapeutics stock in a transaction that occurred on Tuesday, April 4th. The shares were sold at an average price of $11.17, for a total transaction of $78,190.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director William James Kennedy sold 8,548 shares of TG Therapeutics stock in a transaction that occurred on Tuesday, April 11th. The shares were sold at an average price of $10.27, for a total transaction of $87,787.96. The disclosure for this sale can be found here. Insiders own 19.00% of the company’s stock. About TG Therapeutics

TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes.

Related posts

Leave a Comment